DELRAY BEACH, Fla., Sept. 6, 2011 (GLOBE NEWSWIRE) -- PositiveID Corporation ("PositiveID" or "Company") (OTCBB:PSID), a developer of medical technologies for diabetes management, clinical diagnostics and bio-threat detection, announced today that M. Allen Northrup, Ph.D., CEO of the Company's MicroFluidic Systems ("MFS") subsidiary, will present at the SPIE Security + Defense Exhibition on September 19, 2011, at the Clarion Congress Hotel in Prague. Northrup will present at the Sensing and Screening II session of the conference, number 8189A Optics and Photonics for Counterterrorism and Crime Fighting. The SPIE Exhibition showcases the latest technology innovations and future applications, specializing in detection, imaging, lasers, and a multitude of supporting mechanisms and devices. SPIE Security + Defense is the leading defense and security event in Europe.
Northrup's presentation will focus on the Company's Microfluidics-based Bioagent Networked Detector (M-BAND™), a fully integrated bioaerosol monitoring system with sample collection, processing and detection modules. Under independent evaluation, the M-BAND has demonstrated fully autonomous detection and identification of biothreat agents in the field, including in outdoor settings, transportation centers and public areas. The Company's multi-agent detection biological assay for the top U.S. Centers for Disease Control and Prevention biothreat agents, now available commercially, will be described in detail, as well as how its capabilities are being expanded into additional biological pathogen assays for E. coli and others.
About PositiveID Corporation
PositiveID Corporation develops unique medical devices and biological detection systems, focused primarily on diabetes management, rapid medical testing and airborne bio-threat detection. Its wholly-owned subsidiary, MFS, is focused on the development of microfluidic systems for automated preparation of and performance of biological assays. For more information on PositiveID, please visit www.PositiveIDCorp.com.
The PositiveID Corporation logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=7717
Statements about PositiveID's future expectations, including the likelihood that under independent evaluation, the M-BAND has demonstrated fully autonomous detection and identification of biothreat agents in the field, including in outdoor settings, transportation centers and public areas; the likelihood that the Company's multi-agent detection biological assay for top U.S. Centers for Disease Control and Prevention biothreat agents will be expanded into additional biological pathogen assays for E. coli and others; and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and PositiveID's actual results could differ materially from expected results. These risks and uncertainties include PositiveID's ability to commercialize its M-BAND product; as well as certain other risks. Additional information about these and other factors that could affect the Company's business is set forth in the Company's various filings with the Securities and Exchange Commission, including those set forth in the Company's 10-K filed on March 25, 2011, and 10-Qs filed on May 13, 2011 and August 15, 2011, under the caption "Risk Factors." The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.